Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Nat Med. 2015 Mar 30;21(4):344–352. doi: 10.1038/nm.3830

Figure 4.

Figure 4

AR directly interacts with menin. (a) Purified untagged full-length (FL) AR was incubated with purified menin, ASH2L, Max or Ring1b proteins. Anti-AR antibody or control IgG immunoprecipitates (IP) were subjected to immunoblot (IB) analysis using indicated antibodies. (b) Halo-tagged FL-AR or FL-Max was incubated with purified menin. AR was immunoprecipitated using anti-AR and immunoprecipitates were subjected to immunoblot analysis with anti-menin. Immunoblots were stripped and re-probed using anti-Halo. (c) Purified menin was incubated with Halo-tagged FL-AR and FL-Max. Menin was immunoprecipitated using anti-menin and binding to AR was analyzed by immunoblotting with anti-Halo. (d) Schematic representation of Halo-tagged AR truncation mutants used in this study. (e,f) Halo-tagged FL and truncation mutants of AR were incubated with purified menin. Menin was immunoprecipitated and binding to either FL or truncation mutants of AR was analyzed by immunoblot analysis using anti-Halo. The amounts of Halo-tagged proteins used in the pull-down experiments were estimated by anti-Halo immunoblot analysis. All panels show representative blots of three independent experiments.